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EchocardiographyAbstract Background: Hepatopulmonary syndrome (HPS) is an independent predictor of sur-
vival after liver transplantation. Although the prevalence of chronic liver diseases is high in Egypt,
the frequency of HPS among liver transplant candidates (LTC) is unknown.
Aim: To assess the frequency of HPS and factors predictive of diagnosis of HPS in patients with
end-stage liver diseases who are LTC.
Methods: A cross sectional study of patients with end stage liver diseases who are LTC. Patients
were subjected to clinical examination, laboratory investigations, arterial blood gas (ABG) measure-
ment, pulmonary function tests, upper gastrointestinal endoscopy, and transthoracic contrast
enhanced echocardiography (TCEE). The severity of liver disease was assessed by Model for end-
stage liver disease (MELD) score. The diagnostic criteria for HPS were intrapulmonary vascular dila-
tation (IPVD) documented by TCEE, and alveolar-arterial oxygen gradient (A-aDO2)P15 mmHg.
Results: Eighty-four LTC patients were enrolled in the study. Sixteen patients (19%) fulﬁlled the
criteria for diagnosis of HPS. Patients with HPS showed older ages, longer duration of liver diseases
which were more severe (MELD score). Dyspnoea, cyanosis, clubbing, platypnoea, spider naevi and
features of portal hypertension were signiﬁcantly more common in the HPS group. In the recumbent
position; patients with HPS had a signiﬁcantly lower PaO2 and larger A-aDO2 compared to those
without HPS. Patients with HPS showed a further fall in their PaO2 on sitting up (orthodeoxia).
Conclusions: The prevalence ofHPS among the studied group of Egyptian liver transplant candidates
is 19%. Cyanosis, clubbing, spider naevi and platypnoea–orthodeoxia are suggestive indicators of HPS.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.
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Egypt has the highest countrywide prevalence of hepatitis C
virus (HCV) infection in the world [1]. Twenty percent of those
with HCV-hepatitis progress to end stage liver cirrhosis [2].
Liver transplantation is a treatment option for end stage liver
cirrhosis. In cases of liver disease with an indication for trans-
plantation, vascular disorders such as hepatopulmonary syn-
drome (HPS) may develop as a result of hepatocellular
dysfunction or portal hypertension [3]. Hepatopulmonary syn-
drome is associated with a reduced life expectancy [4]. No phar-
macological therapy has thus far consistently been effective in
improving HPS and the only treatment associated to the rever-
sal of HPS in patients with cirrhosis has been liver transplant
and HPS is currently one of the criteria for its anticipation
[5]. Being an independent predictor of mortality and morbidity
after liver transplantation [4]; HPS plays a role in the assess-
ment and follow-up of liver transplant candidates (LTC) [3].
Hepatopulmonary syndrome is a pulmonary vascular dis-
order characterized by the triad of chronic liver disease, arte-
rial hypoxaemia and intrapulmonary vascular dilatations
(IPVD) [6]. In all patients with chronic liver disease and hyp-
oxaemia, the diagnosis of HPS requires documentation of
IPVD. The most common tools are contrast echocardiography
and technetium99m-labelled macroaggregated albumin perfu-
sion scanning. The latter technique is used both for the diagno-
sis of HPS and quantiﬁcation of the magnitude of shunting [6].
The objective of the present study was to determine the preva-
lence of HPS in a sample of Egyptian patients with end-stage liver
diseases who are LTC; and to compare demographic, clinical, and
laboratory characteristics in patients with and without HPS.
Patients and methods
Patients
Adult patients with end stage liver disease who are LTC were
selected from outpatient clinics or inpatient wards of the depart-
ments of Internal Medicine, Mansoura University Hospitals.
Exclusion criteria
1- Primary pulmonary disease such as chronic obstructive
pulmonary disease.
2- Abnormal CXR (e.g. pleural effusion, pneumonia or
atelectasis).
3- Heart failure.
4- Patients with smoking history.
Methods
1- Thorough clinical history and physical examination.
2- Blood Tests: Complete blood picture, urea and creati-
nine, liver function tests, viral markers for hepatitis C
and B.
3- The Model for End-Stage Liver Disease (MELD) score:
This is a waiting list positioning criteria that is based on
liver disease severity [7]. The MELD score ranges from 6
to 40, with higher values indicating more severe disease.
This system has ideal model characteristics, since it isbased on few parameters (all of them objective). These
parameters are easily obtainable and reproducible and
provide a score standard with an excellent capability
for prognoses regarding the risk of death among LTC
[8]. The advantage of this system over the previous sys-
tem, which used the duration of the wait for the trans-
plant (chronological criterion), lies in the fact that it
reduces the mortality rate by prioritizing urgent cases
[9]. The MELD score was calculated using the original
formula without including the cause of liver disease;
MELD score = 0.957 · loge (creatinine mg/
dL) + 0.378 · loge (bilirubin mg/dL) + 1.120 · loge
(INR) + 6.43.
4- Upper gastrointestinal endoscopy.
5- Abdominal ultrasound: to conﬁrm the presence of liver
cirrhosis and/or portal hypertension.
6- Arterial blood gas (ABG): samples were obtained by
radial arterial puncture in recumbent position and after
being upright for 20 min to detect orthodeoxia ‘‘deﬁned
as PaO2 fall by 5% in the upright position as compared
to recumbency value [10]’’.
7- Spirometry: performed using a computed spirometer
(Jaeger, Germany) to rule out primary pulmonary dis-
eases. Spirometry was performed 3 times and the best
effort of FEV1, FVC and FEV1/FVC was recorded.
8- Chest X-ray (CXR]: to rule out cardiac or pulmonary
diseases and to exclude other causes of hypoxaemia such
as emphysema or ﬁbrosis.
9- Transthoracic contrast enhanced echocardiography
(TCEE): Patients with A-aDO2P 15 mmHg under-
went a TCEE [11]. Apical four-chamber imaging was
used for the simultaneous visualization of the atria and
ventricles. Peripheral venous access was obtained
through the forearm. A three-way stopcock was
attached and two 10 mL syringes were connected to
the other two ports. One 10 mL syringe was empty (with
air removed) and the other was ﬁlled with saline solu-
tion. The microbubbles were produced manually by
ﬂushing the saline solution from one syringe to the other
10 times. The agitated solution was then quickly admin-
istered in the peripheral vein with the patient in the
upright position and the second-harmonic imaging was
performed. The test was considered positive when
microbubbles were detected in the left heart chambers
between four and six heart cycles following opaciﬁcation
of the right chambers; and was considered negative if
there was no passing of microbubbles to the left cham-
bers. Visualization of microbubbles in the left chambers
prior to the fourth heartbeat was considered evidence of
intracardiac shunt [12]. Three examinations were per-
formed on each patient and each subsequent injection
was initiated after the disappearance of the microbub-
bles from all cavities. The diagnosis of HPS was based
on identifying IPVD through TCEE, and A-aDO2 -
P 15 mmHg [12].
Statistical analysis
Quantitative data were expressed as means ± standard devia-
tions while qualitative data were expressed as numbers (per-
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out HPS; Student’s t-test was used for quantitative data and
Pearson’s chi-square test for qualitative data. A p value
<0.05 was considered signiﬁcant. Data were analysed using
the Statistical Package for Social Sciences (SPSS, Chicago, IL).
Results
Prevalence of HPS
Eighty-four LTC patients were enrolled in the study. Sixteen
patients (19%) fulﬁlled the criteria for diagnosis of HPS.
Characteristics of patients with HPS
Table 1 shows the demographic and clinical characteristics of
patients with and without HPS. There were no signiﬁcant dif-
ferences between patients with and without HPS regarding
gender and causes of liver disease. Patients with HPS showed
older ages, longer duration of liver diseases which were more
severe (MELD score). Dyspnoea, cyanosis, clubbing, platyp-
noea and spider naevi were signiﬁcantly more common in
the HPS group. Features of portal hypertension (PH) (oesoph-
ageal varices, dilated portal vein and enlarged spleen) were sig-
niﬁcantly more common in the HPS group.
Table 2 shows the spirometric and ABG values in patients
with and without HPS. No signiﬁcant differences were found
between groups regarding FVC and FEV1. In the recumbent
position; patients with HPS had a signiﬁcantly lower PaO2
compared to those without HPS. Patients with HPS showed
a further decrease in their PaO2 on sitting up (orthodeoxia).
Patients with HPS had a signiﬁcantly larger A-aDO2 compared
to those without HPS. No signiﬁcant differences were found
between groups regarding PaCO2.Discussion
Until recently, the diagnostic criteria for HPS were not stan-
dardized, which resulted in a wide variation in the reported
prevalence of the syndrome, as well as in difﬁculties in compar-
ing studies [13]. According to the 2004 ABG standards for the
diagnosis of HPS [12], the prevalence of the syndrome in the
present study was 19%. The prevalence of HPS ranges from
5% to 32% among candidates for liver transplant [14],
depending on the cut-off point of ABG values used for diagno-
sis. We reviewed the literatures for the Egyptians studied look-
ing at the prevalence of HPS among LTC. However; only
studies looking at the prevalence of HPS among patients with
liver cirrhosis and portal hypertension were found. These
studies showed a wide variation in the HPS prevalence
[11.5% [15], 10% [16] and 34% [17]]. We found 3 Brazilian
studies that looked at the prevalence of HPS among LTC.
Lima et al. [18] studied LTC using an A-aDO2 of 20 mmHg
as a cut-off point. They reported a HPS prevalence of 16%;
however, when the A-aDO2 cut-off point was lowered to
15 mmHg, the prevalence of HPS was 27% [4]. Ferreira
et al. reported a HPS prevalence of 15% among LTC using
an A-aDO2 cut-off point of 15 mmHg [19]. The HPS preva-
lence among LTC was 45.5%, 38.6%, and 29.5% when A-
aDO2 cut-off points of 15 mmHg, 16 mmHg, and 20 mmHgwere used, respectively, in Macedo study [20]. The difference
between our prevalence and that reported by these barzilian
studies could be explained by aetiological, racial and geo-
graphical factors as suggested before [21] e.g. in Macedo study;
the most common cause of cirrhosis was alcohol use while
none of our patients had alcoholic cirrhosis.
Although PaO2 has the greatest predictive value, A-aDO2 is
the most sensitive index for determining gas exchange abnor-
malities and A-aDO2P 15 mmHg at sea level (breathing
ambient air) can be considered abnormal. In the present study,
only patients with A-aDO2P 15 mmHg underwent TCEE to
identify patients with diagnostic criteria of HPS. Thus, the rec-
ommendations of the European Respiratory Society [12]
regarding the tracking of HPS in LTC were followed. A similar
diagnostic strategy has also been employed by other authors
[22,23]. Spirometric and radiological evaluations of these
patients are important steps to exclude other diseases that
can contribute to oxygenation alterations, although the exis-
tence of other lung diseases does not exclude the diagnosis of
HPS [24].
Contrast echocardiography was proved to be a sensitive
and speciﬁc screening test for HPS even in early stages of liver
dysfunction where the lung scintigraphy was still negative [25].
Contrast echocardiography was used for the diagnosis of
IPVD both in the recumbent and the upright positions. The
latter method, which was used in our study, was proved by pre-
vious investigators to be more yielding as regards diagnosis of
HPS than that performed to patients in the recumbent position
[26]. This ﬁnding is similar to platypnea and orthodeoxia
which are explained by the preferential circulation to the basal
areas of the lungs in the upright position, as these areas were
assumed to be more affected by intrapulmonary dilatation
and/or shunting [27].
No differences were found between patients with and with-
out HPS in terms of gender which is in accordance with previ-
ous studies [18,22,15,20]. Patients with HPS showed older ages,
longer duration of liver diseases which were more severe
(MELD score). These ﬁndings are further supported by previ-
ous reports showing HPS to be more common in patients with
hepatic changes that were more severe [14,19,15,16,28]. This
correlation between the severity of liver affection and the
development of HPS was explained by increased release of
mediators such as endothelin-1, tumour necrosis factor alpha,
nitric oxide, and carbon monoxide secondary to liver injury,
resulting in IPVD [29]. As all this cascade was dependent on
liver injury, it was suggested to be positively correlated with
the degree of liver function deterioration. On the other hand;
other investigators failed to show a relation between HPS diag-
nosis and the duration and/or the severity of liver disease
[18,20,22,].
Dyspnoea, cyanosis, clubbing, platypnoea and spider naevi
were signiﬁcantly more common in the HPS group. In agree-
ment with these results, Gaber et al., Zakaria et al., Alizadeh
et al. and Hira et al. [15,16,28,30] previously showed these clin-
ical features to be signiﬁcantly more common in patients with
HPS. In contrast, Macedo et al. showed no difference between
patients with and without HPS regarding their clinical history
and physical examination [20].
Features of portal hypertension (PH) (oesophageal varices,
dilated portal vein and enlarged spleen) were signiﬁcantly more
common in the HPS group. The association of HPS and PH
has been documented by other authors [6,31,32]. This suggests
Table 1 Demographic and clinical characteristics of patients with and without hepatopulmonary syndrome.
Variables HPS-positive (n= 16) HPS-negative (n= 68) P value
Age (years) 71.3 ± 9.4 57.21 ± 8.6 <0.05
Gender
Male 10 (62.5%) 37 (54.4%) NS
Female 6 (37.5%) 31 (45.6%)
Duration of liver disease (years) 6.8 ± 2.3 3.7 ± 2.1 <0.01
Severity of liver disease (MELD) 17.1 ± 3.8 13.23 ± 2.77 <0.05
Aetiology of liver disease
Hepatitis C virus 11(68.75%) 51(75%) NS
Hepatitis B virus 3 (18.75%) 10 (14.7%)
Auto-immune 1 (6.25%) 3 (4.4%)
Cryptogenic 1 (6.25%) 4 (5.9%)
Dyspnoea 15 (93.75%) 33 (48.53%) <0.01
Cyanosis 12 (75%) 0 <0.001
Clubbing 11 (68.75%) 6 (8.8%) <0.001
Platypnoea 6 (37.5%) 0 0.001
Spider naevi 8 (50%) 15 (22.06%) <0.05
Oesophageal varices 7 (43.75%) 10 (14.7%) <0.01
Abdominal ultrasound:
Dilated portal vein (>12 mm) 10 (62.5%) 21 (30.88%) <0.05
Enlarged spleen (>120 mm) 16 (100%) 40 (58.82%) <0.001
NS: not signiﬁcant, MELD: Model for End-Stage Liver Disease Score.
Table 2 Spirometric and arterial blood gas values in patients with and without hepatopulmonary syndrome.
Variables HPS-positive (n= 16) HPS-negative (n= 68) P value
FVC (% of predicted) 85.2 ± 14.9 91.8 ± 11.6 NS
FEV1 (% of predicted) 82.5 ± 12.2 90.1 ± 15.7 NS
PaO2 recumbent (mmHg) 67.2 ± 3.5 92.3 ± 6.2 <0.01
PaO2 upright (mmHg) 55.6 ± 4.6
* 93.6 ± 8.9 <0.05
PaCO2 (mmHg) 37.6 ± 5.2 35.9 ± 8.5 NS
A-aDO2 (mmHg) 25.6 ± 12.1 12.3 ± 6.7 <0.01
NS: not signiﬁcant, FVC: forced vital capacity, FEV1: forced expiratory volume in one second, PaO2: partial pressure of
oxygen in arterial blood, PaCO2 partial pressure of CO2 in arterial blood, A-aDO2: alveolar-arterial oxygen difference.
* signiﬁcantly different from PaO2 in the recumbent position (P< 0.05)
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and that hepatic venous return to the pulmonary circulation
is important in maintaining normal pulmonary vascular hemo-
dynamics. The bypassing of the normal intrahepatic venous
ﬂow may trigger a downstream imbalance in vasoactive medi-
ators, leading to vasodilatation [32].
PaO2 was signiﬁcantly lower in the HPS group. A further
fall in PaO2 in the upright position was noted in HPS patients.
This ﬁnding (Orthodeoxia) was reported previously by other
investigators in HPS patients [15,16,20]. Alizadeh et al. [28],
Hira et al. [30], as well as Wang and Lin [33] considered ortho-
deoxia as a suggestive indicator of HPS. As mentioned before;
this ﬁnding was suggested to be similar to platypnea i.e. the
gravitational effect of the upright position shifts blood to areas
of IPVD and shunting in HPS. However in our study some
HPS patients with orthodeoxia did not report platypnea, sug-
gesting that these two conditions did not necessarily go
together. Platypnea is a symptom i.e. dyspnoea may be per-
ceived by the HPS patient without special attention to worsen-
ing of the condition while standing.The present study demonstrated the occurrence of HPS in a
signiﬁcant proportion of patients with end-stage liver disease
who are LTC (especially those with PH). Considering the high
prevalence of HCV cirrohosis in Egypt, we can speculate that
HPS affects a signiﬁcant number of individuals in this popula-
tion and that it is necessary to increase the awareness of health-
care providers regarding the recognition of this condition.
Further studies are needed in order to obtain a better under-
standing of the natural history of HPS and assess the impact
of this ﬁnding on patients’ quality of life and determine
whether there is reversibility or progression following speciﬁc
treatment such as splenectomy, which is often performed in
patients with PH.
In conclusion, HPS affects 19% of the studied group of
Egyptian patients who are liver transplant candidates and
can be easily diagnosed by ABG analysis and contrast echocar-
diography. Dyspnoea, cyanosis, clubbing, spider naevi and
platypnoea are the suggestive indicators of HPS, detection of
these clinical manifestations mandates further evaluation to
conﬁrm the diagnosis of HPS.
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